CALL FOR ABSTRACTS

Abstract and Early Rate Deadline: August 31

Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
New York, NY
Today, more than 10,000 hematopoietic cell transplantations (HCTs) are performed yearly in the United States as treatment for more than 70 life threatening illnesses including cancers, genetic disorders, and other diseases. Also, given the shift toward cellular therapies in the field of HCT, the number of patients treated with these novel biologic agents is rapidly increasing.

Following the successful examples of the international symposia focusing on GVHD and relapse after HCT, this symposium will bring together experts and thought leaders from around the world in the fields of HCT, cellular therapies, and related medical subspecialties. Speakers will discuss mechanisms of toxicities and symptom burden after HCT and cellular therapies, current advances in the field, and best practices to both prevent and treat these toxicities and symptoms.

The target audience for this symposium includes physicians, researchers, fellows, advanced practice providers, nurses, and pharmacists who provide care for patients undergoing HCT and cellular therapies.

Educational Objectives

- Understand the mechanisms of the most common treatment-related toxicities after HCT and cellular therapy.
- Identify best practices to prevent and treat toxicities and symptom burden after HCT and cellular therapy to improve the patient experience and reduce non-relapse mortality.
- Understand how to approach prevention and treatment of toxicities and symptom burden in unique HCT and cellular therapy patient populations.

Call for Abstracts

Abstracts for the poster session will be selected on the basis of scientific merit and content quality. Abstract submission is open to all, and we also highly encourage fellows, residents, pharmacists, and advanced practice providers to submit relevant abstracts in the area of biology, prevention, and treatment of toxicities after transplantation and cellular therapy. In addition, abstracts related to trials and/or clinical research in progress will be accepted. Top awarded abstracts will receive a travel grant tied to attending this symposium.

Submission Deadline: August 31, 2019
This symposium will bring together experts and thought leaders from around the world in the fields of HCT, cellular therapies, and related medical subspecialties. Speakers will discuss mechanisms of toxicities and symptom burden after HCT and cellular therapies, current advances in the field, and best practices to both prevent and treat these toxicities and symptoms.

Course Directors

Sergio A. Giralt, MD
Memorial Sloan Kettering Cancer Center

Michael Scordo, MD
Memorial Sloan Kettering Cancer Center

William A. Wood, MD
UNC Lineberger Comprehensive Cancer Center

Organizing Committee

Miguel Perales, MD
Memorial Sloan Kettering Cancer Center

Bipin N. Savani, MD
Vanderbilt-Ingram Cancer Center

Maria Cancio, MD
Memorial Sloan Kettering Cancer Center

Shernan Holtan, MD
University of Minnesota

David Faleck, MD
Memorial Sloan Kettering Cancer Center

Kenneth R. Cooke, MD
Johns Hopkins Sidney Kimmel Cancer Center

Gabriela Rondon, MD
MD Anderson Cancer Center

Minoo Battiwalla, MD, MS
Sarah Cannon Center for Blood Cancer

Navneet S. Majhail, MBBS, MD, MS
Cleveland Clinic

Invited Course Faculty

Keynote Speaker
Amy Abernethy, MD, PhD
Food and Drug Administration

Andrea Bacigalupo, MD
Policlinico A. Gemelli
Rome, Italy

Department of Medicine Grand Rounds Lecturer
George McDonald, MD
Fred Hutchinson Cancer Research Center

Rajni Agarwal-Hashmi, MD
Stanford

Andrew Artz, MD, MS
City of Hope

Ami Bhatt, MD, PhD
Stanford

Sita Bhella, MEd, MD
University of Toronto

Kira Bona, MD, MPH
Dana Farber/Boston Children's

Chris Breideson, MD, MSc, FRCP
Ottawa Hospital Research Institute
Ottawa, ON, Canada

Mitchell Cairo, MD
New York Medical College

Louis Cohen, MD
Mt Sinai

Christopher Dandoy, MD, MS
Cincinnati Children's Hospital Medical Center

Christine Duncan, MD
Dana Farber/Boston Children's

Areej R. El-Jawahri, MD
Massachusetts General Hospital

Mareike Frick, MD
Charite UMC
Berlin, Germany

MSK Course Faculty

Peter Bach, MD, MAPP

JJ Boelens, MD, PhD

Karen Syrjala, PhD
Fred Hutchinson Cancer Research Center

Amy Abernethy, MD, PhD

Christian Otto,
MD, MMSc, DABFM

Andrea Bacigalupo, MD

Melissa Hudson, MD
St. Jude Children's Research Hospital

Richard J. Jones, MD
Johns Hopkins

Benjamin Laskin, MD, MS
Children's Hospital of Philadelphia

Hillard Lazarus, MD, FACP
University Hospitals Cleveland Medical Center

Caroline Lindemans, MD, PhD
UMC Utrecht
Utrecht, Netherlands

Thomas Luft, MD, PhD
Heidelberg University Hospital
Heidelberg, Germany

Kerry McMillen, MS, RD, CSO, FAND
Fred Hutchinson Cancer Research Center

Pawel Muranski, MD
Columbia University Medical Center

Stefan Nierkens, PhD
UMC Utrecht
Utrecht, Netherlands

Pavan Reddy, MD
University of Michigan Comprehensive Cancer Center

Mscc.org/toxicities
FRIDAY, OCTOBER 11

7:00 AM  Registration and Breakfast

7:50 AM  Welcome, Opening Remarks and Conference Overview
Sergio A. Giralt, MD
Michael Scordo, MD

Gastrointestinal Toxicity, Nutrition and the Microbiome
MODERATORS: David Faleck, MD and Kenneth R. Cooke, MD

8:00 AM  Department of Medicine Grand Rounds
GI and Hepatobiliary Complications of HCT
George McDonald, MD

9:00 AM  EN v. PN – Nutritional Supplementation Early After HCT – Enteral or Parenteral?
Kerry K. McMillen, MS, RD, CSO, FAND

9:20 AM  Emerging Evidence on the Pathobiology and Biomarkers of Regimen-Related Mucosal Injury
Pavan Reddy, MD

9:40 AM  Mechanisms of Gastrointestinal Injury in HCT – Learning from IBD
Louis Cohen, MD

10:00 AM  Q&A with Speakers

10:15 AM  Break

Mechanisms of Toxicity
MODERATORS: Miguel-Angel Perales, MD and Shernan Holtan, MD

10:30 AM  Accelerated Functional Aging and Sarcopenia After HCT
Jessica M. Scott, MD

10:50 AM  Association of the Pulmonary Virioma and Post-HCT Pulmonary Toxicities
Caroline Lindemans, MD, PhD

11:10 AM  Strategies to Improve Immune Reconstitution After HCT and Novel Cellular Therapies
Stefan Nierkens, PhD

11:30 AM  Association of Patient and Donor Clonal Hematopoiesis with HCT Toxicities
Mareike Frick, MD

11:50 AM  Harmonizing Conditioning Regimens – How PK/PD Impacts Toxicities and Outcomes
JJ Boelens, MD, PhD

12:10 PM  Q&A with Speakers

Lunch Breakout Seminars

12:45 PM  Harnessing Biotech Innovations and Telemmedicine Potential in HCT and Cellular Therapies
MODERATORS: William A. Wood, MD
Michael Scordo, MD
SPEAKERS: Chris Bredeson, MD, MSc, FRCP, Christian Otto, MD, MMSc, DABFM

12:45 PM  Using Dynamic Scoring Systems to Predict and Prevent NRM After HCT
MODERATORS: Sergio A. Giralt, MD
SPEAKERS: Thomas Luft, MD, PhD
Andrea Bacigalupo, MD

2:15 PM  Chronic Disease Burden in Survivors of Childhood HCT
Melissa Hudson, MD

2:35 PM  Toxicities and Outcomes in the Geriatric Patient After HCT and Cellular Therapies
Andrew Artz, MD, MS

2:55 PM  “It Takes a Village” – Impact of Psychosocial Risk on HCT Outcomes
Karen Szyjala, PhD

3:15 PM  Patient-Reported Outcomes and Symptom Burden After CAR T Cell Therapy
Navneet Majhail, MD, MS

3:35 PM  End-of-Life Care in HCT: What Do HCT Physicians Think About Palliative Care?
Areej R. El-Jawahri, MD

3:55 PM  Q&A with Speakers

4:10 PM  Break

The Cost of HCT and Cellular Therapies – From Symptoms, to Pockets, and Beyond
MODERATORS: Minoo Battiwalla, MD, MS and Gabriela Rondon, MD

4:25 PM  Choosing Wisely in HCT and Its Applicability to Novel Cellular Therapies
Sita Bhella, MD, MS

4:45 PM  Are CAR T Cells and Novel Cellular Therapies Cost-effective?
Peter Bach, MD, MAPP

5:05 PM  The Short and Long-Term Costs of Critical Illness After HCT and Cellular Therapies
Christine Duncan, MD

5:25 PM  Impact of Financial and Socioeconomic Burden on HCT Outcomes
Kira Bona, MD, MPH

5:45 PM  Importance of Standardizing Cause-specific Death Adjudication After HCT and Cellular Therapies
Theresa Hahn, PhD

6:05 PM  Q&A with Speakers

Networking Reception & Poster Abstract Session
Course attendees are invited to join the faculty for a networking reception and poster abstract session immediately following the conclusion of day one from 6:15-7:30 pm in the lobby of Zuckerman Research center. Hors d’oeuvres and refreshments will be served.
SUNDAY, OCTOBER 12

7:30 AM Breakfast

Morning Seminar/Debate
MODERATORS: Hillard Lazarus, MD, FACP and Kenneth R. Cooke, MD

8:00 AM
Harmonizing VOD/SOS Diagnosis and Classification
Mitchell Cairo, MD
Richard J. Jones, MD
George McDonald, MD

Keynote Address
8:50 AM
Harnessing Technology, Big Data, and PROs to Reduce Toxicities and Symptoms After HCT and Cellular Therapy
Amy Abernethy, MD, PhD

Investigational Research in Toxicities – From Bench to Bedside
MODERATORS: Navneet S. Majhail, MBBS, MD, MS and Bipin N. Savani, MD

9:35 AM
Use of Non-Genotoxic Conditioning to Mitigate Regimen-Related Toxicity
Rajni Agarwal-Hashmi, MD

10:00 AM
The Injured Endothelium in HCT Toxicities
Christopher Dandoy, MD, MS

10:25 AM
Virus specific T cells to Mitigate Infectious Complications After HCT
Pawel Muranski, MD

10:45 AM
Break

11:05 AM
Human Microbiome in Hematopoiesis and Immune Recovery After HCT and Cellular Therapies
Ami Bhatt, MD, PhD

11:25 AM
Novel Biomarkers of Acute and Chronic Renal Injury After HCT and Cellular Therapies
Benjamin Laskin, MD, MS

11:45 AM
Incorporating Biomarkers of Non-GVHD Toxicity in Clinical Trial Design
Shernan Holtan, MD

12:05 PM
Q&A with Speakers

Keynote Address
12:20 PM
Preventing All-Cause Death after HCT – What Should be our Focus when Designing Trials?
Andrea Bacigalupo, MD

1:00 PM Symposium Adjourn

REGISTRATION

REGISTRATION FEES

<table>
<thead>
<tr>
<th></th>
<th>EARLY*</th>
<th>GENERAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians (MDs, PhDs, PharmDs and DOs)</td>
<td>$350</td>
<td>$400</td>
</tr>
<tr>
<td>Advanced Practice Providers, Nurses, and Other Healthcare Providers</td>
<td>$200</td>
<td>$250</td>
</tr>
<tr>
<td>Residents, Fellows</td>
<td>$150</td>
<td>$200</td>
</tr>
<tr>
<td>Industry Professionals**</td>
<td>$650</td>
<td>$700</td>
</tr>
</tbody>
</table>

*Early registration rates available through August 31, 2019.

**Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

Register online:
mskcc.org/toxicities

Course registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary requests or require any specific accommodations.

• MSK CME offers a discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners. If you are a member of one of these groups, please contact cme@mskcc.org for more information.

• MSK employee registration is complimentary. However, you must complete course registration in order to attend this course.

Location & Accommodations

Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street
New York, NY

MSK has negotiated special rates and amenities at select hotels in Manhattan. For information on hotels in the vicinity of MSK with discounted rates, visit: mskcc.org/cme

mskcc.org/toxicities
Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**AMA Credit Designation Statement**
MSK designates this live activity for a maximum of 14.50 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

**Faculty Disclosure**
It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.